000 03004nam a22003735i 4500
001 293238
003 MX-SnUAN
005 20160429155058.0
007 cr nn 008mamaa
008 150903s2014 sz | o |||| 0|eng d
020 _a9783034807098
_99783034807098
024 7 _a10.1007/9783034807098
_2doi
035 _avtls000345376
039 9 _a201509030331
_bVLOAD
_c201405050320
_dVLOAD
_y201402061335
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM1-950
100 1 _aTrifilieff, Alexandre.
_eeditor.
_9325681
245 1 0 _aIndacaterol :
_bThe First Once-daily Long-acting Beta2 Agonist for COPD /
_cedited by Alexandre Trifilieff.
264 1 _aBasel :
_bSpringer Basel :
_bImprint: Springer,
_c2014.
300 _avii, 146 páginas 41 ilustraciones, 21 ilustraciones en color.
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aMilestones in Drug Therapy,
_x2296-6056
500 _aSpringer eBooks
505 0 _aCurrent Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies – lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD?  .
520 _aChronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled ?2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783034807081
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-0348-0709-8
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c293238
_d293238